The world of economics is in a constant state of flux and has shifted from an essentially US-based focus to Asia's point of convergence. After many years of driving economic growth, the pull of global wealth has shifted and is now largely concenrated in this region, and we analyse its structural success.
Pacific Alliances specialises in finding the best fund managers in Asia to create a unique, diversified portfolio that will aim to generate the best risk-adjusted returns for your portfolio. The in-house research team assess all investments prior to purchase to maximise returns on investment and minimise risks in a environment of due diligence.
The firm today announced today that it would invest in Acadia Pharmaceuticals while continuing to provide a range of fund administration services for over a billion in assets under management.
Acadia Pharmaceuticals develops and commercialises small molecule drugs for the treatment of central nervous system disorders. Acadia is following up on the gains that were seen previously with the stock.
According to Jonathan Brooks, the firm's portfolio manager and senior analyst responsible for research on emerging market economies in Asia, said, "It seems that after the announcement that Pfizer would be acquiring Anacor Pharmaceuticals, investors have been looking for the next possible acquisition, and the overwhelming opinion seems to be that the acquisition will Acadia Pharmaceuticals.
"However, Acadia has a long history of collaborating with Allergan and it will be interesting to see whether the company will be willing to pay upwards of $6 billion to $7 billion for it. Despite rumours of an early acquisition, I have an distinctly bullish opinion of what we can expect to see from Acadia Pharmaceuticals.
"It has several strong products that have already been approved and are on the market and these factors, in combination with a strong team and great management, will lead to long-term gains."
According to data from S&P Global Market Intelligence, Acadia Pharmaceuticals' stock rose by nearly 10 per cent in May and this monthly surge was fuelled by the company setting a wholesale price of its newly approved Parkinson's disease drug, Nuplazid, which could generate upwards of $4 billion in peak sales within the US alone.
About Pacific Alliances
Established in 2005, Pacific Alliances offer wealth management advice to high-net-worth individuals and corporations, which is tailored to suit their varying needs and circumstances. It offers sound and trustworthy financial advice to create diversified portfolios that generate the best possible risk-adjusted returns.
Hillary joined Pacific Alliances in 2009. She started her career in Sydney, Australia, where she was responsible for their international equity exposure. In 2001 Hillary was named Chief Investment Officer of the Asset Management Strategy Partnership and in 2003, she moved to Asia.